Abstract
Several alternative treatments exist for patients with clinically localized prostate cancer who have Gleason grades equal to or less than 7. Though an adequate randomized prospective study comparing these various treatment modalities has not been performed, many series of outcomes of treatment of patients with clinically localized prostate cancer exist. If in fact one of these treatments is more effective than the other, the difference is likely very small and could only be delineated in a very large randomized prospective trial. As is well recognized, these treatments include radical prostatectomy, external beam radiation therapy, and brachytherapy. Fortunately, because of the well-recognized stage migration of prostate cancer associated with the widespread use of prostate-specific antigen (PSA) testing, most patients diagnosed with prostate cancer are in this so-called “good risk” category.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Cadeddu JA, Partin AW, Epstein JI, et al (1997) Stage Di (T1-3, N1-3, MO) prostate cancer: a case controlled comparison of conservative treatment versus radical prostatectomy. Urology 50:251
DeKernion JB, Neuwirth H, Stein A, et al (1990) Prognosis of patients with stage Di prostate carcinoma following radical prostatectomy with and without early endocrine therapy. J Urol 144:700
Frazier HA, Robertson JE, Paulson DF. (1994) Does radical prostatectomy in the presence of positive pelvic lymph nodes enhance survival? World J Urol 12:308
Koch MO, Foster RS, Brandli DW, et al (2000) Biochemical disease free survival in patients with high PSA (20–100 ng/ml), stage TxNo prostate cancer after radical prostatectomy. J Urol 163:284
Kupelian P, Katcher J, Levin H, et al (1997) External beam radiotherapy versus radical prostatectomy for clinical stage T1–2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores. Cancer J Sci Am 3:78
Lu-Yao GL. and Yao SL. (1997) Population-based study of long term survival in patients with clinically localized prostate cancer. Lancet 349:906
Messing EM, Manola J, Sarosdy M, et al (1999) Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer. N Engl J Med 341:1781
Ohori M, Goad JR, Wheeler TM, et al (1994) Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 152:1843
Paulson DF, Cline WA, Koefoot, RB, et al (1982) Extended field radiation therapy versus delayed hormonal therapy in node positive prostate adenocarcinoma. J Urol 127:935
Sgrignol AR, Walsh PC, Steinberg GD, et al (1994) Prognostic factors in men with stage Di prostate cancer: identification of patients less likely to have prolonged survival after radical prostatectomy. J Urol 152:1077
Wawroschek F, Vogt H, Weckermann D, et al (1999) The sentinel lymph node concept in prostate cancer-first results of gamma probe-guided sentinel lymph node identification. Eur Urol 36:595
Zincke H, Bergstralh EJ, Larson-Keller JJ, et al (1992) Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Cancer 70:311
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Foster, R.S. (2003). Is Radical Lymphadenectomy Indicated in Lymph Node-Positive Disease?. In: Hofmann, R., Heidenreich, A., Moul, J.W. (eds) Prostate Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56321-8_25
Download citation
DOI: https://doi.org/10.1007/978-3-642-56321-8_25
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62643-2
Online ISBN: 978-3-642-56321-8
eBook Packages: Springer Book Archive